1. Home
  2. GLTO vs MGOL Comparison

GLTO vs MGOL Comparison

Compare GLTO & MGOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLTO
  • MGOL
  • Stock Information
  • Founded
  • GLTO 2011
  • MGOL 2018
  • Country
  • GLTO Denmark
  • MGOL United States
  • Employees
  • GLTO N/A
  • MGOL N/A
  • Industry
  • GLTO Biotechnology: Pharmaceutical Preparations
  • MGOL Advertising
  • Sector
  • GLTO Health Care
  • MGOL Consumer Discretionary
  • Exchange
  • GLTO Nasdaq
  • MGOL Nasdaq
  • Market Cap
  • GLTO 6.5M
  • MGOL 7.3M
  • IPO Year
  • GLTO 2020
  • MGOL 2023
  • Fundamental
  • Price
  • GLTO $5.50
  • MGOL $0.48
  • Analyst Decision
  • GLTO Buy
  • MGOL
  • Analyst Count
  • GLTO 1
  • MGOL 0
  • Target Price
  • GLTO $10.00
  • MGOL N/A
  • AVG Volume (30 Days)
  • GLTO 21.2K
  • MGOL 6.1M
  • Earning Date
  • GLTO 03-07-2025
  • MGOL 11-14-2024
  • Dividend Yield
  • GLTO N/A
  • MGOL N/A
  • EPS Growth
  • GLTO N/A
  • MGOL N/A
  • EPS
  • GLTO N/A
  • MGOL N/A
  • Revenue
  • GLTO N/A
  • MGOL $5,197,527.00
  • Revenue This Year
  • GLTO N/A
  • MGOL N/A
  • Revenue Next Year
  • GLTO N/A
  • MGOL N/A
  • P/E Ratio
  • GLTO N/A
  • MGOL N/A
  • Revenue Growth
  • GLTO N/A
  • MGOL 47.01
  • 52 Week Low
  • GLTO $4.40
  • MGOL $0.36
  • 52 Week High
  • GLTO $23.50
  • MGOL $18.30
  • Technical
  • Relative Strength Index (RSI)
  • GLTO 52.98
  • MGOL 23.38
  • Support Level
  • GLTO $4.60
  • MGOL $0.51
  • Resistance Level
  • GLTO $5.98
  • MGOL $0.66
  • Average True Range (ATR)
  • GLTO 0.42
  • MGOL 0.09
  • MACD
  • GLTO 0.08
  • MGOL 0.05
  • Stochastic Oscillator
  • GLTO 65.22
  • MGOL 5.29

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

About MGOL MGO Global Inc.

MGO Global Inc has built a brand acceleration platform with a focus on the acquisition, optimization and monetization of consumer brands across multiple categories. Its mission is to provide customers with unmatched variety, quality and shopping experience. The Company has three reportable segments: 1) The Messi Store, which sells a range of products under The Messi Brand; 2) Stand Flagpoles, which sells a range of residential flagpoles and related products direct to consumers; and 3) Corporate, which generates no revenue, but reflects corporate expenses related primarily to being a public company.

Share on Social Networks: